Zahra Habibagahi; Mohammad Ali Nazarinia; Elham Aflaki; Akbar Rajaee
Volume 4, Issue 3 , December 2007, , Pages 161-166
Abstract
Background: The clinical significance of antiphospholipid antibodies in patients with chronic hepatitis C virus (HCV) and some other viral infections is controversial. Objective: To study the prevalence of anticardiolipin antibody (ACLA) and antibeta2glycoproteinI antibody (antibeta2GPI antibody) in ...
Read More
Background: The clinical significance of antiphospholipid antibodies in patients with chronic hepatitis C virus (HCV) and some other viral infections is controversial. Objective: To study the prevalence of anticardiolipin antibody (ACLA) and antibeta2glycoproteinI antibody (antibeta2GPI antibody) in HCV and hepatitis B virus (HBV) infected patients and its association with liver clinical parameters. Methods: Serum levels of ACLA, antibeta2GPI antibody as well as platelet count, ALT (alanine transaminase), PT (prothrombine time), disease duration and liver histologic findings of 38 patients with HBV and 15 patients with HCV infections were compared with those of 58 healthy controls. Results: Serum titres of ACLA in HCV and HBV patients (13.4 ±7.1 GPL units/ml), and in each of the HCV (15.18±9.91 GPL units/ml) and HBV (12.7 ± 5.7 GPL units/ml) patients were significantly higher than that of the control group (3.4±2.3GPL units/ml). However, there was no significant difference in serum levels of antibeta2GPI antibody from patients with HCV and HBV (3.3 ± 1.3 GPL units/ml) or HCV alone (2.79 ± 1.01 GPL units/ml) or HBV alone (3.4±1.3GPL units/ml) and that of the control group (3.3±1.1GPL units/ml). Conclusion: The findings suggest that the presence of ACLA has no pathologic significance in patients with HBV and HCV infections.
Sara Kashef; Reza Amin; Maryam Ayatollahi; Abbas Ghaderi
Volume 1, Issue 2 , September 2004, , Pages 117-123
Abstract
Background: Antiphospholipid antibody syndrome (APS) can either occur as a primary syndrome or associated with other autoimmune diseases such as systemic lupus erythematosus (SLE). Anticardiolipin antibody (aCL) of IgG and/or IgM isotype in blood, measured by a standardized ELISA is the most acceptable ...
Read More
Background: Antiphospholipid antibody syndrome (APS) can either occur as a primary syndrome or associated with other autoimmune diseases such as systemic lupus erythematosus (SLE). Anticardiolipin antibody (aCL) of IgG and/or IgM isotype in blood, measured by a standardized ELISA is the most acceptable laboratory criteria. APS IgG isotype, particularly IgG2 subclass is more strongly associated with thrombosis. Objectives: This study was done to determine the prevalence of IgG aCL and its subclasses in relation to APS symptoms, in a group of juvenile rheumatoid arthritis (JRA) and juvenile systemic lupus erythematosus (SLE) patients. Methods: In this prospective study, 28 JRA and 16 SLE patients, aged 3-18 years, were enrolled. IgG aCL was assayed by standard aCL ELISA. IgG subclasses were also assayed by ELISA on sera with medium to high titers of aCL. ACL assay was performed on at least two occasions for each patient, over 3-6 months period of follow up. Results: 29% (8/28) of JRA patients and 44% (7/16) of SLE patients had aCL. Six of SLE patients displayed APS related manifestations: hemolytic anemia, thrombocytopenia, arterial occlusion, valvular heart disease, livedo reticularis and pulmonary hypertension, but none of them had persistant medium or high titer of aCL. The lack of association of high titer of aCL with APS related symptoms was observed in two patients. The IgG subclasses were primarily IgG1 and IgG3. Conclusion: The prevalence of IgG aCL in this group of pediatric SLE and JRA is not uncommon but it’s relation to clinical manifestations is not clear. IgG1 and IgG3 subclasses were not associated with thrombosis, which is in agreement with previous studies.